Genus plc (GNS.L)
Operating quietly across the globe, Genus uses science and genetics to help farmers breed healthier, more productive livestock.
Is Genus plc a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: A world leader in specialised animal genetics with deep scientific expertise. Worth weighing: Revenue growth has stalled recently with flat year-on-year figures. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Genus plc actually fallen?
Over the last 2 years of daily prices, Genus plc fell as much as −38% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Strong demand for sustainable food production cements the company as an indispensable industry partner.
Alternative proteins drastically reduce traditional livestock farming demand.
What does Genus plc do?
This British firm sits at the intersection of agriculture and bioscience, applying advanced genetics to pigs and cattle so farmers can produce food more efficiently. It makes its money by selling high-performing breeding stock and semen that pass on desirable traits like disease resistance. Keep a close eye on how quickly its research translates into actual sales, especially when farming markets hit a rough patch.
On our factor screen it looks strongest on growth and quality, and weakest on momentum.
- ✓Pays a dividend - about 1.5% a year
- !High P/E of 31 - big growth is already priced in
- A world leader in specialised animal genetics with deep scientific expertise
- Essential role in global food supply chains provides steady baseline demand
- Clear separation from standard technology or cyclical industrial firms
- Value screens low (23/100)
- Momentum screens low (15/100)
- Outbreaks of animal diseases can suddenly halt the movement or sale of breeding stock
- Changes in international trade rules can complicate the global transport of biological products
- Heavy reliance on ongoing scientific research paying off commercially
What do Genus plc's numbers mean?
Does Genus plc pay a dividend?
Yes - Genus plc currently pays a dividend of about 1.5% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about Genus plc's dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
When does Genus plc report earnings, and how did recent quarters go?
Genus plc is next scheduled to report on about 2026-09-10 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Genus plc?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Genus plc?
How many points the write-up makes each way — a balance check, not a score or verdict.
- A world leader in specialised animal genetics with deep scientific expertise
- Essential role in global food supply chains provides steady baseline demand
- Clear separation from standard technology or cyclical: A business whose sales and profits rise and fall with the wider economy - booming in good times, sinking in downturns. Miners, carmakers and banks are classic examples. industrial firms
- Revenue growth: How fast the company's sales grew versus a year ago. has stalled recently with flat year-on-year figures
- Modest net profit margin means small cost increases can pinch profits
- Vulnerable to unpredictable farming industry cycles and livestock diseases
- Outbreaks of animal diseases can suddenly halt the movement or sale of breeding stock
- Changes in international trade rules can complicate the global transport of biological products
- Heavy reliance on ongoing scientific research paying off commercially
The write-up's own warning lights — if these start happening, the case above changes.
- A prolonged contraction in global livestock farming budgets
- Major regulatory blocks on key genetic editing products
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.